Related Experiment Video
Updated: Jul 15, 2026
09:01
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Innovative therapeutics for inflammatory bowel disease.
1Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Vasco de Quiroga 15, Col. Seccion XVI, Tlalpan, Mexico CP 14000, DF Mexico. kazuofurusho@hotmail.com
World Journal of Gastroenterology
|April 28, 2007
Summary
Inflammatory bowel diseases (IBD) involve chronic gastrointestinal inflammation. New therapies aim to improve treatment effectiveness and safety by targeting inflammation at various levels.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic gastrointestinal inflammatory conditions.
- Current treatments for IBD involve aminosalicylates, corticosteroids, and immunosuppressants.
Purpose of the Study:
- To review and classify novel therapeutic strategies for IBD based on recent advances in understanding disease pathophysiology.
- To highlight the potential of these new therapies to offer improved efficacy and safety profiles for IBD patients.
Main Methods:
- Literature review and classification of emerging IBD therapies.
- Categorization based on the targeted level of inflammatory processes.
Main Results:
- Ten categories of new IBD therapies were identified: Anti-TNFalpha antibodies, recombinant cytokines, selective adhesion blockade, growth factors, innate immunostimulation, nucleic acid-based therapies, gene therapy, autologous bone-marrow transplantation, helminths, and extracorporeal immunomodulation.
- These therapies target diverse mechanisms within the inflammatory cascade.
Conclusions:
- Advances in IBD research have led to a broad spectrum of innovative therapeutic approaches.
- These novel treatments hold promise for more effective and safer management of inflammatory bowel diseases.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...